



Please print and sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/786,720
		Filing Date	February 26, 2004
		First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
		Group Art Unit	1634
		Examiner Name	Carla J. Myers
Total Number of Pages in This Submission	6	Attorney Docket Number	031896-023000 (AM101329)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s): PTO Form-1449 citing two (2) U.S. patent, two (2) foreign patent and thirty-two (32) non-patent literature documents, including one (1) International Search Report
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-023000) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Raymond Van Dyke, Reg. No. 34,746 Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	October 12, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.	
Date	Signature



Docket No. 031896-023000
(AM101329)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)

Margot Mary O'TOOLE *et al.*) Group Art Unit: 1634

Serial No.: 10/786,720) Examiner: Carla J. Myers

Filed: February 26, 2004) Confirmation No.: 2740

For: COMPOSITIONS AND METHODS)
FOR DIAGNOSING AND TREATING)
AUTOIMMUNE DISEASES)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

The documents cited in the enclosed Form-PTO-1449 are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

In view of the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patent documents are not included with this Statement. However, copies of the cited foreign patent and non-patent literature documents, as well as the International Search Report from a related international patent application, are enclosed.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing, which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,


Date: October 15, 2005

By:



Raymond Van Dyke
Registration No. 34,746

NIXON PEABODY LLP
Customer No. 50839
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
(202) 585-8000



Substitute for form 1449				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/786,720
				Filing Date	February 26, 2004
				First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Carla J. Myers
Sheet	1	of	3	Attorney Docket Number	031896-023000 (AM101329)

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		U.S. - 6,506,559	01/14/2003	FIRE <i>et al.</i>	
		U.S. - 5,498,531	03/12/1996	JARRELL	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO - 1997/07668 A1	03/06/1997	CAMPBELL <i>et al.</i>		
		WO - 1997/07669 A1	03/06/1997	CAMPBELL <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SUN, X.-Z. <i>et al.</i> , An immunohistochemical study of radial glial cells in the mouse brain prenatally exposed to gamma-irradiation, <i>J. Neuropathol Exp Neurol</i> , 56(12):1339-1348, 1997	
		KADOMATSU, K. <i>et al.</i> , Midkine induces the transformation of NIH3T3 cells, <i>Br J Cancer</i> , 75(3):354-359, 1997	
		CHOUDHURI, R. <i>et al.</i> , An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis, <i>Cancer Res.</i> , 57(9):1814-1819, 1997	
		TAKEI, Y. <i>et al.</i> , Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells, <i>Cancer Res.</i> , 61(23):8486-8491, 2001	
		TAKEI, Y. <i>et al.</i> , 5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy, <i>J. Biol. Chem.</i> , 277(26):23800-23806, 2002	
		INUI, T. <i>et al.</i> , Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds, <i>J. Peptide Sci.</i> , 2(1):28-39, 1996	
		MURAMATSU, H. <i>et al.</i> , Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule, <i>Biochem. Biophys. Res. Commun.</i> , 203(2):1131-1139, 1994	
		ASAI, T. <i>et al.</i> , Identification of heparin-binding sites in midkine and their role in neurite-promotion, <i>Biochem. Biophys. Res. Commun.</i> , 236(1):66-70, 1997	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/786,720
				Filing Date	February 26, 2004
				First Named Inventor	Margot O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Carla J. Myers
Sheet	2	of	3	Attorney Docket Number	031896-023000 (AM101329)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		KANEDA, N. <i>et al.</i> , Structural characteristics of heparin-line domain required for interaction of midkine with embryonic neurons, <i>Biochem. Biophys. Res. Commun.</i> , 220(1):108-112, 1996		
		PEDRAZA, C. <i>et al.</i> , A retinoic acid-responsive element in human midkine gene, <i>J. Biochem. (Tokyo)</i> , 117(4):845-849, 1995		
		AHMED, K. M. <i>et al.</i> , Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer, <i>Cancer Lett.</i> , 180(2):159-63, 2002		
		AHMED, K. M. <i>et al.</i> , Genetic variations of the midkine (MK) gene in human sporadic colorectal and gastric cancers, <i>Int. J. Mol. Med.</i> , 6(3):281-287, 2000		
		URIOS, P. <i>et al.</i> , Molecular cloning of RI-HB, a heparin binding protein regulated by retinoic acid, <i>Biochem. Biophys. Res. Commun.</i> , 175(2):617-627, 1991		
		NAIR, S. M. <i>et al.</i> , Expression of HNK-1 carbohydrate and its binding protein, SBP-1, in apposing cell surfaces in cerebral cortex and cerebellum, <i>Neuroscience</i> , 85(30):759-771, 1998		
		LEE, N. S. <i>et al.</i> , Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, <i>Nat. Biotechnol.</i> , 20(5):500-505, 2002		
		ALTSCHUL, S. F. <i>et al.</i> , Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, <i>Nucleic Acids Res.</i> , 25(17):3389-3402, 1997		
		GUATELLI <i>et al.</i> , Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication, <i>Proc. Natl. Acad. Sci. USA</i> , 87(5):1874-1878, 1990. Erratum in: <i>Proc. Natl. Acad. Sci. USA</i> , 87(19):7797, 1990		
		KWOH, D. Y. <i>et al.</i> , Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format, <i>Proc. Natl. Acad. Sci. USA</i> , 86(4):1173-1177, 1989		
		LIZARDI, P. M. <i>et al.</i> , Exponential amplification of recombinant-RNA hybridization probes, <i>Bio-Technology</i> , 6:1197-1202, 1988		
		O'GORMAN, S. <i>et al.</i> , Recombinase-mediated gene activation and site-specific integration in mammalian cells, <i>Science</i> , 251(4999):1351-1355, 1991		
		WILMUT, I. <i>et al.</i> , Viable offspring derived from fetal and adult mammalian cells, <i>Nature</i> 385(6619):810-813, 1997. Erratum in: <i>Nature</i> , 386(6621):200, 1997		
		MISHIMA, K. <i>et al.</i> , Increased expression of midkine during the progression of human astrocytomas, <i>Neurosci. Lett.</i> , 233(1):29-32, 1997		
		TSUTSUI, J. <i>et al.</i> , A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas, <i>Cancer Res.</i> , 53(6):1281-1285, 1993		
		KUROSAWA, N. <i>et al.</i> , Midkine binds specifically to sulfatide the role of sulfatide in cell attachment to midkine-coated surfaces, <i>Eur. J. Biochem.</i> , 267(2):344-351, 2000		
		ZOU, K. <i>et al.</i> , A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican, <i>Eur. J. Biochem.</i> , 267(13):4046-4053, 2000		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/786,720	
				Filing Date		February 26, 2004	
				First Named Inventor		Margot O'TOOLE <i>et al.</i>	
				Art Unit		1634	
				Examiner Name		Carla J. Myers	
Sheet	3	of	3	Attorney Docket Number		031896-023000 (AM101329)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		SAID, E. A. <i>et al.</i> , The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor, <i>J. Biol. Chem.</i> , 277(40):37492-37502, 2002		
		STOICA, G. E. <i>et al.</i> , Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types, <i>J. Biol. Chem.</i> , 277(39):35990-35998, 2002		
		IKEDA, S. <i>et al.</i> , Effects of midkine during <i>in vitro</i> maturation of bovine oocytes on subsequent developmental competence, <i>Biol. Reprod.</i> , 63(4):1067-1074, 2000		
		KATO, M. <i>et al.</i> , Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses, <i>Liver</i> , 20(3):216-221, 2000		
		International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages		
		IWASAKI, W. <i>et al.</i> , Solution structure of midkine, a new heparin-binding growth factor, <i>EMBO J.</i> , 16(23):6936-6946, 1997		
		MYERS, E.W. and MILLER, W., Optical alignments in linear space, <i>CABIOS</i> , 4(1):11-17, 1988		
		TSUTSUI, J. <i>et al.</i> , A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse, <i>Biochem. Biophys. Res. Commun.</i> , 176(2):792-797, 1991		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.